Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Jan 11, 2023 3:25pm
145 Views
Post# 35216644

RE:Repurchases so far from NCIB

RE:Repurchases so far from NCIB
GoldenInvestor wrote: - has there been more than the 450k, as recently discussed?

- with total NCIB potential , when management sees favourable, they could originally  Re-purchase up to almost 8,000,000 shares.

- so with approximately the 7,500,000 possible share redemption remaining, and operations continuing to evolve at a less restrictive, or adaptive post-covid pace, profits from increasing sales will be going to significantly less shares.


Of the 8M shares that we can purchase, we've purchased a little over 2.5M from my calculations. It's a slower pace than last year but we're on pace for ~5M shares, which would bring us to around 110M shares.

Totally agree on your last statement and that's why share buybacks are so powerful with rising earnings / cash flow. 
<< Previous
Bullboard Posts
Next >>